Chai Discovery

Today, we’re releasing new data showing that Chai-2 can design antibodies against challenging targets with atomic precision. In June, we introduced Chai-2, showing it could design antibodies zero-shot in a 24-well plate. In this new data, we show that Chai-2 can: 💡Design full-length mAbs, with >86% of designs showing developability characteristics on par with approved therapeutics, while maintaining the high hit rates we previously reported. 🔬Achieve atomic-level precision on epitope targeting, with Cryo-EM structures matching model designs across five antibody-antigen complexes 🏁 Generate binders and functional agonists against a panel of six GPCRs, which are notoriously hard-to-drug targets. Testing just <75 designs for each, we obtain a binder in every case (median hit rate: 21%). We discover functional agonists to two distinct GPCR targets. 🔎 Design antibodies for peptide-MHC that discriminate single-residue mutations, including binders specific to KRAS G12V over G12D and wild-type peptides These results provide a glimpse into a new paradigm, where drug designs are conceived on the computer and predictive models approach the precision of the wet lab. Thank you to many partners for making this possible: Oracle, Mithril, Amazon Web Services (AWS), NVIDIA, Modal for compute; Sino Biological, GenScript for conducting many wet-lab experiments in the paper.

🚀 Chai Discovery has been named to the Endpoints News 11 list of the most promising biotech companies of 2025! This annual recognition celebrates the most ambitious and innovative biotech startups. In just 12 months since announcing our first funding round, we’ve raised $100M and launched Chai-2: our AI model that can design antibodies on the computer with double-digit success rates. This award reflects our team’s relentless focus on transforming biology from science into engineering. There's no reason to believe the capabilities should plateau here. We look forward to pushing the boundaries of what’s possible at the intersection of biotech and AI.

Hear directly from our founder Joshua Meier and Mikael Dolsten about the work we are planning together and the breakthroughs ahead. Welcome aboard, Mikael Dolsten! 🚀

🎙️ Listen to this episode of Unsupervised Learning with Jacob Effron of Redpoint Ventures, where our co-founder Joshua Meier shares how Chai Discovery is building AI foundation models that are advancing what’s possible in biotech. Chai’s latest model, Chai-2, achieved a 20% lab-validated hit rate across 50 molecular targets — more than 200× higher than past industry attempts. In this episode, you'll hear about: 📊 From data to design: how Chai-2 was built via improvements across the stack ⚡ What's changing: how fast AI molecule generation enables testing many biological hypotheses in parallel 🚀 Why now: stronger base models, more compute, and mature cross-domain AI techniques delivering reliable lab results Listen here: ▶️ Youtube: https://lnkd.in/eUSA8TJF 🎵 Spotify: https://lnkd.in/e_JXfyQt 🍏 Apple: https://lnkd.in/ebH2uQdq

Thank you Nasdaq! We're excited to continue pushing the boundaries of molecular design with AI at Chai Discovery.

🎉 Congratulations to Zhuoran Qiao for winning the Tianqiao and Chrissy Chen Institute and Science Magazine AI Prize, recognizing his groundbreaking AI research in biochemistry. We’re honored to have him on the Chai Discovery team!

Listen to today's #NoPriorsPod to hear why the Chai Discovery team is bullish on biotech. Thank you to Sarah Guo for hosting Jack Dent and Joshua Meier.